Результаты поиска

Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.

BACKGROUND: Rheumatoid arthritis is a chronic autoimmune disease that primarily causes inflammation, pain and stiffness in the joints. Peopl … ira®; AbbVie, Inc., North Chicago, IL, USA), etanercept (Enbrel®; Pfizer, Inc., New York, NY, USA), infliximab (Remicade®, Merck Sharp & Dohme Limited, Hoddesdon, UK), certolizumab pegol (Cimzia®; UCB Pharma Limited, Slough, UK) and golimumab (Simponi®; Merck Sharp & Dohme Limited)] in people with rheumatoid arthritis who had either achieved treatment target …

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.

BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis … ity Index costs. The optimal treatment is not sensitive to the use of biosimilar prices for ETN and infliximab (REMICADE®, Merck Sharp & Dohme, Kenilworth, NJ, USA). CONCLUSIONS: SEC and CZP may be an effective use of NHS resources, depending on the subpopulation and subgroup of psoriasis severity. There are a number of limitations to this assessment, drive …

Терапевтическое применение иммунобиологии в аутоиммунных и воспаленных заболеваниях.

Иммунобиологика или биологическая экспертиза революционизировали терапевтическую парадигму аутоиммунных и подстрекательских заболеваний путем выборочного целеопределения и модуляции дисрегулированных иммунных путей. По сравнению с обычными широкоспектральными иммунопрепрессантами биологика обеспечивает более конкретный и основанный на механизмах рациональный подход, зачастую связанный с повышением эффективности и сокращением неблагоприятных явлений. В этом обзоре содержится всеобъемлющий обзор репертуара терапевтической биологики, механизмов их действий, важнейших клинических испытаний и клини

Совпадение в полном тексте источника
… Infliximab (IFX) Infliximab is a chimeric mouse-human IgG1 monoclonal antibody that specifically targets TNF-α, a key pro-inflammatory cytokine involved in the pathogenesis of multiple autoimmune and inflammatory disorders. … In an ex vivo porcine model of retinal degeneration, infliximab attenuated Zaprinast-induced retinal degeneration, which arises from inhibition of cGMP-degrading phosphodiesterase 6 (PDE6), indicating infliximab’s neuroprotective potential [ 157 ]. …

Cumulative thalidomide exposure, peripheral neuropathy, and clinical outcomes in pediatric and very early-onset inflammatory bowel disease: a retrospective cohort study.

BackgroundThalidomide serves as a rescue therapy for refractory pediatric Inflammatory Bowel Disease (pIBD), but its use is constrained by the risk of thalidomide-induced Peripheral Neuropathy (TiPN). The quantitative relationship between cumulative dose and TiPN, as well as the risk profile in the specific population of Very Early-Onset IBD (VEOIBD), lacks precise evaluation.MethodsWe conducted a single-center, retrospective cohort study of children with IBD treated with thalidomide from 2018 to 2025. We compared cumulative thalidomide doses between TiPN and non-TiPN groups and employed ROC c

Совпадение в полном тексте источника
… Within two years of diagnosis, up to 50% of pIBD patients require escalation to biologic therapy. 5 , 6 , 7 Real-world evidence demonstrates significantly reduced remission rates and elevated infliximab discontinuation in VEOIBD compared to older pediatric cohorts, 6 , 8 infliximab induction frequently … Earlier reports indicated that only 19%–36% of VEOIBD patients on infliximab continued treatment beyond 12-months. …

Investigative biological therapies for primary Sjögren's syndrome.

Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease characterized by dryness of the eyes and mouth. The histological feature is mononuclear cell infiltration in exocrine glands, primarily salivary and lachrymal glands. As the disease progresses, some other tissues and organs may be involved and extraglandular manifestations ensue. The major current treatments are palliative and empirical, and in most cases the outcomes are not satisfactory. Emerging data indicate a critical role of lymphocytes in its development and progression. While pioneering work targeting B cells ha

Совпадение в полном тексте источника
… Infliximab, a chimeric mAb against TNF-α, was the first biologic used in pSS. … Infliximab in patients with primary Sjögren’s syndrome: a pilot study . Arthritis Rheum 2001 ; 44 : 2371 - 5 . 11665979 10.1002/1529-0131(200110)44:10<2371::aid-art401>3.0.co;2-w 53 Steinfeld SD , Demols P , Appelboom T . Infliximab in primary Sjögren’s syndrome: one-year followup . …

Treatment of sarcoid granulomatous interstitial nephritis with adalimumab.

Sarcoidosis is a systemic disease with multiorgan involvement which can cause renal failure through several different mechanisms. Granulomatous interstitial nephritis is an important albeit less frequent cause of clinically significant renal disease. Herein, we present the case of a 46 year old woman with a history of sarcoidosis whom we evaluated for rapidly worsening kidney function and proteinuria. Renal biopsy revealed granulomatous interstitial nephritis. After therapy with adalimumab, her renal function improved with a significant reduction in proteinuria. Repeat kidney biopsy showed res

Совпадение в полном тексте источника
… Adalimumab is administered subcutaneously, whereas infliximab is administered intravenously. From an economic standpoint, infliximab administration requires more health care resources with requirements for infusion suites and equipment as well as medical and nursing supervision [ 12 ]. … The shared mechanism of action of infliximab and adalimumab may explain the positive response in our case. …

[Surgical treatment of ulcerative colitis: a 10-year retrospective analysis at a surgical referral center].

Objective: To investigate the clinical characteristics, postoperative complications, and risk factors for pouchitis in surgical patients wit … %) had used biopharmaceuticals within 2 months prior to surgery, 63 (18.8%) of them having received infliximab. A smaller proportion of patients had undergone surgery for UC that was refractory to medications in the 2020-2024 group than in the 2014-2019 group (73.0% [130/178] vs. 83.5% [132/158], χ2=5.384, P=0.020), the patients were older at colectomy (48.0 …

A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.

Productivity costs can strongly impact cost-effectiveness outcomes. This study investigated the impact in the context of expensive hospital drugs. This study aimed to: (1) investigate the effect of productivity costs on cost-effectiveness outcomes, (2) determine whether economic evaluations of expensive drugs commonly include productivity costs related to paid and unpaid work, and (3) explore potential reasons for excluding productivity costs from the economic evaluation. We conducted a systematic literature review to identify economic evaluations of 33 expensive drugs. We analysed whether eva

Совпадение в полном тексте источника
… Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. Int. J. Technol. Assess. Health Care. 2007;23:368–375. doi: 10.1017/S0266462307070432. 38. … The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J. Rheumatol. 2006;33:732–740. 44. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am. J. …

Синдром Нейро-Бехчета: доклад по делу.

Синдром Бехчета является системным васкулитом, характеризующимся повторяющимися оральными и генитальными язвами, увеитизмом и часто связанным с множественными системами органов. Неврологическое участие является редким осложнением синдрома Бехчета и связано со значительной заболеваемостью и смертностью. Синдром Neuro-Behchet (NBS) представляет собой сочетание неврологических проявлений у пациента с синдромом Бехчета, включая расстройства движения, миэлопатический синдром, внутричерепную гипертонию и многократную склероз-подобную презентацию. Диагноз NBS может быть проблематичным из-за широкого

Совпадение в полном тексте источника
… FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging At this time, the patient reported compliance with outpatient infliximab, which raised concern for acute disseminated encephalomyelitis as a potential complication of infliximab therapy. … For moderate disease, azathioprine (2 mg/kg/day) or methotrexate (0.3 mg/kg/week) may be used, while serious disease may require cyclophosphamide IV or an anti-TNF-alpha such as infliximab [ 13 ]. In this case, imaging originally suggested that demyelination was secondary to infliximab use. …

Serious infections associated with anticytokine therapies in the rheumatic diseases.

The ability to target and neutralize macrophage-derived inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), has emerged in recent years as one of the most important advances in the treatment of rheumatoid arthritis, Crohn's disease, and several other systemic inflammatory diseases. In rheumatoid arthritis, for example, these biological agents rapidly reduce signs and symptoms of joint inflammation and profoundly slow the progression of joint damage. However, data that have emerged following Food and Drug Administration approval of these agents have alerted clinicians

The Pathophysiology and Treatment of Pyoderma Gangrenosum-Current Options and New Perspectives.

Pyoderma gangrenosum (PG) is an uncommon inflammatory dermatological disorder characterized by painful ulcers that quickly spread peripherally. The pathophysiology of PG is not fully understood; however, it is most commonly considered a disease in the spectrum of neutrophilic dermatoses. The treatment of PG remains challenging due to the lack of generally accepted therapeutic guidelines. Existing therapeutic methods focus on limiting inflammation through the use of immunosuppressive and immunomodulatory therapies. Recently, several reports have indicated the successful use of biologic drugs an

Совпадение в полном тексте источника
… At week 2, significantly more patients in the infliximab group observed improvement (46%) compared with the placebo group (6%). Patients from the placebo group, without a response, were offered infliximab. Overall, 29 patients received infliximab, with 69% demonstrating adequate results. … In PG, infliximab is administered in standard doses, i.e., 5 mg/kg at weeks 0, 2, and 6, followed by infusions every 6 to 8 weeks. Several retrospective analyses were performed in patients with PG receiving infliximab. …

Neurologic adverse events of cancer immunotherapy.

Cancer immunotherapy encompasses a wide range of treatment modalities that harness the anti-tumor effects of the immune system and have revolutionized oncological treatment in recent years, with approval for its use in more and more cancers. However, it is not without side effects. Several neurological adverse events have been recognized associated with immune checkpoint inhibitors (ICI) and chimeric antigen receptor (CAR) T-cell therapy, the two main classes of cancer immunotherapy. With the increase in the prevalence of oncological diseases and this type of therapy, it is improbable that neu

Совпадение в полном тексте источника
… Treatment with tacrolimus, rituximab, infliximab, and mycophenolate has also been reported 10 . The vast majority of patients with this condition had good responses to treatment. … The two patients who used infliximab had isolated myelitis refractory to steroids and PLEX or IVIG, with improved neurological symptoms with the anti-TNF-α 16 . …

Visceral adiposity and inflammatory bowel disease.

BACKGROUND: Rates of obesity are increasing worldwide, as is the incidence of inflammatory bowel disease (IBD). Obesity is now considered an … taneous fat Visceral fat Total abdominal fat increased 18% in Crohn's disease patients treated with infliximab induction therapy Shen [35] 2018 China Retrospective N = 97 N/A Crohn's disease CT (umbilicus) Subcutaneous fat area Visceral fat area Mesenteric fat index VFA and MFI were significantly lower in patients with mucosal healing (post-infliximab). (p < …

Прогрессивная многофукальная лейкоэнцефалопатия в реуматоидном артрите и биологической терапии: доклад по делу и обзор литературы.

Прогрессивная многофукальная лейкоэнцефалопатия - это редкое, но потенциально смертельное заболевание, вызванное инфекцией центральной нервной системы с полиомавирусом Джона Каннингема. Прогрессивная многофукальная лейкоэнцефалопатия встречается главным образом у иммунокомпромиссированных пациентов, включая пациентов с биологическими и адресными синтетическими препаратами, такими, как множественный склероз и ревматоидный артрит. Ранняя диагностика прогрессивной многофукальной лейкоэнцефалопатии имеет решающее значение для выживания пациента. Мы описываем случай прогрессивной многофукальной лей

Совпадение в полном тексте источника
… Unknown Unknown Unknown Unknown Molloy et al . [ 35 ] USA Male 69 Yes HCQ, CYC Infliximab Unknown Unknown Unknown Death Molloy et al . [ 35 ] The Netherlands Male 69 Cataract, COPD No MTX Rituximab 3 1.5 Word-finding difficulties, trouble reading, uncertain gait Hematoma, vascular 0.25 PCR CSF Death … Unknown Unknown Unknown Unknown Molloy et al . [ 35 ] USA Male 69 Yes HCQ, CYC Infliximab Unknown Unknown Unknown Death Molloy et al . [ 35 ] The Netherlands Male 69 Cataract, COPD No MTX Rituximab 3 1.5 Word-finding difficulties, trouble reading, uncertain gait Hematoma, vascular 0.25 PCR CSF Death …

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade.

BackgroundPneumonitis related to immune checkpoint blockade is uncommon but can be severe, fatal or chronic. Steroids are first-line treatment, however, some patients are refractory or become resistant to steroids. Like many immune-related adverse events, little is known regarding the outcomes and optimal management of patients in whom steroids are ineffective.MethodsWe performed a single-center retrospective cohort study at a high-volume tertiary cancer center to evaluate the clinical course, management strategies and outcomes of patients treated for immune checkpoint pneumonitis with immune

Совпадение в полном тексте источника
… Among all patients, the first-choice additional immune modulators included TNF-alpha blockade (20, 77% of patients; 19 treated with infliximab;1 treated with adalimumab) or mycophenolate mofetil (6, 23% of patients). … The rate of durable pneumonitis improvement with infliximab as the initial immunomodulator was 20% (4/20; 90-day survival: 7/20, 35%) and with mycophenolate was 83% (5/6, 83%; 90-day survival: 6/6, 100%), but it should be noted that infliximab was favored for use in the most severe cases. …

Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?

Clinicians involved in the treatment of inflammatory bowel disease (IBD) increasingly come across patients with current or previous history of malignancies. With increasing and earlier use of immunosuppression and biologics in IBD patients, the question arises whether these treatments further increase the risk of new or recurrent cancers. A number of population-based observational studies have now reported the odds of development of new or recurrent cancers with thiopurines and antitumour necrosis factors (anti-TNFs). These data combined with data arising from treatment registries from other i

Совпадение в полном тексте источника
… patients compared with those who are infliximab naïve. … A multicentre, phase II study of infliximab plus gemcitabin in pancreatic cancer cachexia . J Support Oncol 2008 ; 6 : 18 – 25 . 18257397 16 Jatoi A Ritter HL Dueck A et al . …

SOD1 амиотропический боковой склероз, связанный с нейросаркоидозом: доклад по делу и обзор литературы.

Мы описываем 37-летнего мужчину с сосущественным амиотропическим боковым склерозом (ALS), вызванным мутацией в супероксидном дисмутазе 1 (SOD1) и вероятным нейросаркодом миэлорадикулитом. Согласие этих двух редких условий создает серьезные проблемы с диагностикой и лечением. Мы обсуждаем сроки диагностики, терапевтические меры, результаты более чем за пол десятилетия ухода и обзор соответствующей литературы.

Совпадение в полном тексте источника
… He improved with corticosteroids, infliximab, and mycophenolate. … Subsequent clinical worsening due to anti-infliximab antibodies and suspected tofersen-associated inflammatory exacerbation prompted discontinuation of both agents and initiation of adalimumab, resulting in sustained clinical and radiologic stability. He declined tofersen rechallenge. …

Prosthetic Joint Infection due to Mycobacterium avium-intracellulare in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature.

Nontuberculous mycobacteria (NTM) are a rare cause of prosthetic joint infections (PJI). However, the prevalence of NTM infections may be increasing with the rise of newer immunosuppressive medications such as biologics. In this case report, we describe a rare complication of immunosuppressive therapies and highlight the complexity of diagnosing and treating PJI due to NTM. The patient is a 79-year-old Caucasian male with a history of severe destructive rheumatoid arthritis on several immunosuppressive agents and right hip osteoarthritis s/p total hip arthroplasty 15 years previously with seve

Совпадение в полном тексте источника
… His RA had been treated with prednisone 15 mg daily, leflunomide 10 mg daily, and infliximab. Six months prior to admission infliximab was replaced with abatacept 500 mg every month. At presentation, vital signs were normal. BMI was 22.9 kg/m. … TNF-alpha antagonists, particularly infliximab, predispose patients to mycobacterial infections by blocking macrophage activation and intracellular killing [ 12 ]. …

Biosimilars in Oncology: Latest Trends and Regulatory Status.

Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment and supportive care. Biosimilar medications (or biosimilars) are very similar to the reference biologic drugs, although they are not identical. As patent protection for some of the most extensively used biologics begins to expire, biosimilars have the potential to enhance access and provide lower-cost options for cancer treatment. Initially, r

Совпадение в полном тексте источника
… For instance, clinical trials of biosimilars for chronic inflammatory diseases (i.e., etanercept-szzs, infliximab-abda, adalimumab-atto, and infliximab-dyyb) switched patients from the original biological product to a biosimilar, and no considerable differences in immunogenicity were observed [ 163 , … Patients who were administered an infliximab biosimilar ultimately spent 12% less out of pocket than with the reference biologic, according to a Johns Hopkins study [ 172 ]. …